Belite Bio (NASDAQ:BLTE) Posts Earnings Results, Beats Expectations By $0.26 EPS

Belite Bio (NASDAQ:BLTE) posted its quarterly earnings data on Wednesday. The company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.26, FiscalAI reports.

Here are the key takeaways from Belite Bio’s conference call:

• Belite Bio said it received the phase III clinical study report for Tinlarebant in Stargardt disease and began its NDA rolling submission to the FDA in April, with completion targeted for Q2 2026.
• Management said FDA discussions supported a potential single-study approval path based on the robustness of the DRAGON 1 data, while DRAGON II is primarily intended to satisfy Japan regulatory requirements.
• The company has begun building its commercial organization, with all commercial leadership hired and a planned launch team of about 30 to 40 people focused on disease awareness, genetic testing, and drug promotion.
• Belite Bio remains focused on the Stargardt opportunity first, while its geographic atrophy program is still in development with an interim readout targeted for around end of year and strategy to be determined by the data.
• The company ended Q1 with a strong $799 million cash position after ESOP and warrant proceeds, which management said should fund NDA completion, commercialization prep, and ongoing trials.

Belite Bio Price Performance

BLTE stock opened at $144.25 on Friday. The business has a 50 day simple moving average of $159.99 and a 200-day simple moving average of $156.74. The firm has a market capitalization of $5.76 billion, a PE ratio of -57.02 and a beta of -1.19. Belite Bio has a 1 year low of $56.10 and a 1 year high of $200.00.

Analyst Ratings Changes

A number of brokerages have commented on BLTE. Cantor Fitzgerald lifted their price target on Belite Bio from $200.00 to $266.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 3rd. Mizuho set a $223.00 price objective on Belite Bio in a report on Thursday, February 19th. Weiss Ratings restated a “sell (d-)” rating on shares of Belite Bio in a research note on Tuesday, April 7th. Wall Street Zen upgraded Belite Bio from a “sell” rating to a “hold” rating in a research note on Saturday, April 4th. Finally, HC Wainwright reiterated a “buy” rating and set a $200.00 price objective on shares of Belite Bio in a research note on Thursday. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $202.33.

Insider Activity

In other news, insider Nathan L. Mata sold 666 shares of the company’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $153.21, for a total value of $102,037.86. Following the completion of the sale, the insider directly owned 440 shares in the company, valued at $67,412.40. This represents a 60.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders sold 26,166 shares of company stock valued at $4,548,351 in the last ninety days. 13.29% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Bank of Montreal Can purchased a new position in Belite Bio in the fourth quarter worth approximately $2,499,000. Boothbay Fund Management LLC purchased a new position in Belite Bio in the fourth quarter worth approximately $1,903,000. HRT Financial LP purchased a new position in Belite Bio in the fourth quarter worth approximately $1,305,000. Wellington Management Group LLP purchased a new position in Belite Bio in the fourth quarter worth approximately $991,000. Finally, JPMorgan Chase & Co. grew its position in Belite Bio by 45.2% in the third quarter. JPMorgan Chase & Co. now owns 9,809 shares of the company’s stock worth $726,000 after acquiring an additional 3,052 shares during the period. 0.53% of the stock is currently owned by hedge funds and other institutional investors.

Belite Bio Company Profile

Belite Bio, Inc (NASDAQ: BLTE) is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation.

Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages.